trending Market Intelligence /marketintelligence/en/news-insights/trending/Bi_RZyFzzi7g_LaVzq_pSw2 content esgSubNav
In This List

Pfizer, eFFECTOR enter licensing, collaboration deal to develop cancer therapies

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Pfizer, eFFECTOR enter licensing, collaboration deal to develop cancer therapies

Pfizer Inc. has joined with San Diego-based private biotech eFFECTOR Therapeutics Inc. to develop small-molecule inhibitors of a certain protein that is activated in a number of human cancers.

The collaboration will focus on the development of small-molecule inhibitors of eukaryotic initiation factor 4E, a protein that resists certain cancer treatments and is linked to poor prediction of the disease.

Under the exclusive worldwide license and collaboration agreement, Pfizer will pay eFFECTOR $15 million upfront and up to an additional $492 million in potential development and sales milestone payments.

Additionally, eFFECTOR will receive royalties on sales of any products from the program that reaches the commercialization stage.